Replies to post #120560 on Biotech Values

[ghmm]

I wonder how the stock reacts if VRTX/MRK have successful launches vs. poor launches

If they are too good perhaps people start worrying less patients will be available by the time they get to market.

If they have poor launches maybe people think HCV patients aren't as eager to get treatment as people think.

I've noticed your posting about other genotypes. So I am guessing your hoping for slightly positive launches but limited to Genotype 1 :-).